GB201713163D0 - HPV vaccine - Google Patents

HPV vaccine

Info

Publication number
GB201713163D0
GB201713163D0 GBGB1713163.2A GB201713163A GB201713163D0 GB 201713163 D0 GB201713163 D0 GB 201713163D0 GB 201713163 A GB201713163 A GB 201713163A GB 201713163 D0 GB201713163 D0 GB 201713163D0
Authority
GB
United Kingdom
Prior art keywords
hpv vaccine
hpv
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1713163.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1713163.2A priority Critical patent/GB201713163D0/en
Publication of GB201713163D0 publication Critical patent/GB201713163D0/en
Priority to MX2020001655A priority patent/MX2020001655A/es
Priority to JP2020508007A priority patent/JP7551495B2/ja
Priority to CA3072536A priority patent/CA3072536A1/en
Priority to SG11202001244SA priority patent/SG11202001244SA/en
Priority to KR1020207006062A priority patent/KR102713224B1/ko
Priority to AU2018316734A priority patent/AU2018316734B2/en
Priority to PCT/GB2018/052335 priority patent/WO2019034887A1/en
Priority to US16/639,144 priority patent/US11179456B2/en
Priority to EP18759700.0A priority patent/EP3668542A1/en
Priority to CN201880053063.XA priority patent/CN111212659B/zh
Priority to US17/532,177 priority patent/US12064477B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1713163.2A 2017-08-16 2017-08-16 HPV vaccine Ceased GB201713163D0 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
GBGB1713163.2A GB201713163D0 (en) 2017-08-16 2017-08-16 HPV vaccine
CN201880053063.XA CN111212659B (zh) 2017-08-16 2018-08-16 Hpv疫苗
SG11202001244SA SG11202001244SA (en) 2017-08-16 2018-08-16 Hpv vaccine
JP2020508007A JP7551495B2 (ja) 2017-08-16 2018-08-16 Ｈｐｖワクチン
CA3072536A CA3072536A1 (en) 2017-08-16 2018-08-16 Hpv vaccine
MX2020001655A MX2020001655A (es) 2017-08-16 2018-08-16 Vacuna vph.
KR1020207006062A KR102713224B1 (ko) 2017-08-16 2018-08-16 Hpv 백신
AU2018316734A AU2018316734B2 (en) 2017-08-16 2018-08-16 HPV vaccine
PCT/GB2018/052335 WO2019034887A1 (en) 2017-08-16 2018-08-16 HPV VACCINE
US16/639,144 US11179456B2 (en) 2017-08-16 2018-08-16 HPV vaccine
EP18759700.0A EP3668542A1 (en) 2017-08-16 2018-08-16 Hpv vaccine
US17/532,177 US12064477B2 (en) 2017-08-16 2021-11-22 HPV vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1713163.2A GB201713163D0 (en) 2017-08-16 2017-08-16 HPV vaccine

Publications (1)

Publication Number Publication Date
GB201713163D0 true GB201713163D0 (en) 2017-09-27

Family

ID=59895974

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1713163.2A Ceased GB201713163D0 (en) 2017-08-16 2017-08-16 HPV vaccine

Country Status (11)

Country Link
US (2) US11179456B2 (enExample)
EP (1) EP3668542A1 (enExample)
JP (1) JP7551495B2 (enExample)
KR (1) KR102713224B1 (enExample)
CN (1) CN111212659B (enExample)
AU (1) AU2018316734B2 (enExample)
CA (1) CA3072536A1 (enExample)
GB (1) GB201713163D0 (enExample)
MX (1) MX2020001655A (enExample)
SG (1) SG11202001244SA (enExample)
WO (1) WO2019034887A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201713163D0 (en) 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine
TWI852977B (zh) * 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20220082047A (ko) * 2019-10-16 2022-06-16 캔써 리서치 테크놀로지 리미티드 암 치료용 벡터
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
GB202019767D0 (en) 2020-12-15 2021-01-27 Chain Biotechnology Ltd Compostitions and methods
GB202209115D0 (en) 2022-06-21 2022-08-10 Chain Biotechnology Ltd Compositions and methods
WO2024218165A1 (en) * 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine
WO2025092908A1 (zh) * 2023-11-01 2025-05-08 仁景(苏州)生物科技有限公司 治疗HPV感染相关疾病的mRNA疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026443B1 (en) * 1999-12-10 2006-04-11 Epimmune Inc. Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
CA2552508A1 (en) * 2003-12-31 2005-09-29 Pharmexa Inc. Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions
EA019836B1 (ru) * 2007-11-02 2014-06-30 Те Джонс Хопкинс Юниверсити Композиции многотипных пептидов hpv и способы лечения или предотвращения папилломавирусной инфекции у человека
EP2093410B1 (en) * 2008-02-21 2014-04-09 Delphi International Operations Luxembourg S.à r.l. A fuel injector with an improved valve control arrangement
WO2010123561A1 (en) 2009-04-20 2010-10-28 Arbor Vita Corporation Antibodies specific to e6 proteins of hpv and use thereof
EP2940133A4 (en) * 2012-12-25 2016-07-06 Chemo Sero Therapeut Res Inst VACCINE AGAINST HPV AND / OR HEPATITIS B INFECTION CONTAINING CHIMERIC HPV / HBS PROTEIN AS AN ACTIVE INGREDIENT
CA2898522A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Improved vaccines for human papilloma virus and methods for using the same
EP3518966A1 (en) 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
GB201713163D0 (en) 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine

Also Published As

Publication number Publication date
KR20200056384A (ko) 2020-05-22
CA3072536A1 (en) 2019-02-21
CN111212659A (zh) 2020-05-29
JP2020536489A (ja) 2020-12-17
US11179456B2 (en) 2021-11-23
WO2019034887A1 (en) 2019-02-21
CN111212659B (zh) 2023-09-22
US12064477B2 (en) 2024-08-20
US20220152189A1 (en) 2022-05-19
SG11202001244SA (en) 2020-03-30
EP3668542A1 (en) 2020-06-24
MX2020001655A (es) 2020-08-17
AU2018316734B2 (en) 2025-08-21
JP7551495B2 (ja) 2024-09-17
KR102713224B1 (ko) 2024-10-07
AU2018316734A1 (en) 2020-02-27
US20200306358A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
ZA201904717B (en) Therapeutic hpv18 vaccines
GB201410971D0 (en) Vaccine
ZA201703055B (en) Therapeutic hpv16 vaccines
GB201705765D0 (en) HBV vaccine
GB201518684D0 (en) Vaccine
PL3185899T3 (pl) Wzmocniona szczepionka wektorowa-hvt przeciwko nd-ibd
SG11202001244SA (en) Hpv vaccine
ZA201808121B (en) Therapeutic hpv vaccine combinations
IL267785A (en) virus
GB201522132D0 (en) Vaccine
GB201616904D0 (en) Vaccine
GB201608821D0 (en) Vaccines
HUE053284T2 (hu) Vakcina
GB201419061D0 (en) Conjugated Vaccine
GB201811382D0 (en) Vaccine
GB201603029D0 (en) Vaccine
GB201417214D0 (en) Vaccine
GB201406628D0 (en) Vaccine
HK40029106A (en) Hpv vaccine
GB201712904D0 (en) Vaccine
HK40036700A (en) Vaccine
GB201704126D0 (en) Vaccine
GB201703809D0 (en) Vaccine
GB201717288D0 (en) Hiv vaccine
GB201704892D0 (en) Improved vaccines

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)